Ethic Inc’s Allogene Therapeutics ALLO Stock Holding History

Ethic Inc’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-15,389	Closed	-$21.1K	–	1218
2025 Q1	$21.1K	Buy	+15,389	New	+$29K	﹤0.01%	1154

Other funds holding ALLO

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Ethic Inc's ALLO Position: Q2 2025 in Review

Ethic Inc sold out of Allogene Therapeutics (ALLO) in Q2 2025, closing a stake of 15,389 shares — an estimated $21.1K sold.

Ethic Inc first reported a position in ALLO in Q1 2025 and held it in 1 quarter. The position peaked at $21.1K in Q1 2025. 158 funds tracked by Wall St. Rank hold ALLO as of Q2 2025.

Ethic Inc reported no remaining Allogene Therapeutics position as of Q2 2025 after selling out during the quarter.
Ethic Inc sold 15,389 Allogene Therapeutics shares in Q2 2025, an estimated $21.1K.
Ethic Inc first reported a position in Allogene Therapeutics in Q1 2025 and held it in 1 quarter.
Ethic Inc's Allogene Therapeutics position peaked at $21.1K in Q1 2025.
158 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2025.

Based on Ethic Inc's 13F filing for Q2 2025, filed 30 Jul 2025.